U.S. Markets close in 3 hrs 44 mins
  • S&P 500

    3,559.50
    +1.96 (+0.06%)
     
  • Dow 30

    29,415.33
    +151.85 (+0.52%)
     
  • Nasdaq

    11,833.60
    -21.37 (-0.18%)
     
  • Russell 2000

    1,785.34
    +1.21 (+0.07%)
     
  • Crude Oil

    42.17
    +0.43 (+1.03%)
     
  • Gold

    1,869.60
    +8.10 (+0.44%)
     
  • Silver

    24.23
    +0.18 (+0.74%)
     
  • EUR/USD

    1.1862
    -0.0014 (-0.1186%)
     
  • 10-Yr Bond

    0.8520
    +0.0230 (+2.77%)
     
  • Vix

    23.70
    +0.59 (+2.55%)
     
  • GBP/USD

    1.3291
    +0.0038 (+0.2858%)
     
  • USD/JPY

    103.8280
    +0.0570 (+0.0549%)
     
  • BTC-USD

    18,356.25
    -98.50 (-0.53%)
     
  • CMC Crypto 200

    362.98
    +1.55 (+0.43%)
     
  • FTSE 100

    6,351.45
    +17.10 (+0.27%)
     
  • Nikkei 225

    25,527.37
    -106.93 (-0.42%)
     

Neurocrine: 3Q Earnings Snapshot

·1 min read

SAN DIEGO (AP) _ Neurocrine Biosciences Inc. (NBIX) on Monday reported a third-quarter loss of $57.6 million, after reporting a profit in the same period a year earlier.

On a per-share basis, the San Diego-based company said it had a loss of 62 cents.

The results missed Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of 11 cents per share.

The biopharmaceutical company posted revenue of $258.5 million in the period, which also fell short of Street forecasts. Eleven analysts surveyed by Zacks expected $281.9 million.

Neurocrine shares have fallen nearly 4% since the beginning of the year. In the final minutes of trading on Monday, shares hit $103.64, increasing slightly in the last 12 months.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on NBIX at https://www.zacks.com/ap/NBIX